Clinical trials: Non-atopic
Atopic Dermatitis
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
This is a Prospective, non-interventional (NIS) observational study in patients (≥6 years) with atopic dermatitis (AD) receiving dupilumab for the prospective evaluation of signs and symptoms, quality of life and disease control.
- Trial name
- PROTYPE2 (NCT06039241)
- Where
- 55 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis
The objective of this study is to assess the safety and efficacy of 0.03% tacrolimus ointment as long-term treatment in paediatric patients with atopic dermatitis.
- Trial name
- NCT00560326
- Testing
- Tacrolimus Ointment 0.03%
- Where
- 8 sites in Canada, Finland and 3 more
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Dupilumab in Japanese Patients With Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) Secondary Objective: To evaluate the efficacy of dupilumab administered concomitantly with TCS.
- Trial name
- NCT04678882
- Testing
- Dupilumab SAR231893
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Atopic Dermatitis
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e.
- Trial name
- NCT00925730
- Testing
- Pimecrolimus
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis
Atopic Dermatitis
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic…
- Trial name
- NCT04699695
- Testing
- Biologic therapy versus no biologic therapy
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- DermTech
Atopic Dermatitis, Eczema, Atopic
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months.
- Trial name
- MADULO (NCT05642208)
- Testing
- Dupilumab step-down
- Where
- 32 sites in France, Reunion
- Volunteers
- 256 people
- Sponsor
- Nantes University Hospital
Prurigo Nodularis, Atopic Dermatitis
Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing
Prurigo nodularis (PN) is a skin condition characterized by symmetrically distributed widespread, pruritic nodules that occurs in patients with chronic pruritus.
- Trial name
- PRURISEQ (NCT04681300)
- Testing
- Skin biopsy, Plastic surgery remnants
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bronchial Asthma
Omalizumab in Non-atopic Asthma
Hypothesis- Omalizumab(humanized monoclonal anti-IgE antibody)improves disease control and reduces bronchial mucosal inflammation in non-atopic asthma.
- Trial name
- NCT01113437
- Testing
- Omalizumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- King's College London
Mild and Moderate Atopic Dermatitis Patients, Atopic Dermatitis (AD)
Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a chronic skin disorder, which negatively impacts up to 20% children and 3% adults in the world. The main AD treatments aim to regress clinical manifestations, improve and restore skin lesions.
- Trial name
- NCT07653386
- Testing
- S.formosum-containing ointment, commercial moisturizer
- Where
- Vietnam
- Volunteers
- 90 people
- Sponsor
- VinUniversity
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Atopic Dermatitis
The Effectiveness of Antibacterial Therapeutic Clothing Based on Silver or Chitosan as Compared With Non-antibacterial Therapeutic Clothing in Patients With Moderate to Severe Atopic Dermatitis
Since 2000 therapeutic clothing or functional textiles based on silver or chitosan as antibacterial agents were introduced as therapeutics of atopic dermatitis (AD).
- Trial name
- ABC project (NCT04297215)
- Testing
- DermaCura® Chitosan based antimicrobial therapeutic clothing, Binamed® silver based antimicrobial therapeutic clothing, Binamed® therapeutic clothing without antimicrobial agents
- Where
- Netherlands
- Volunteers
- 165 people
- Sponsor
- Erasmus Medical Center
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Peanut Allergy
Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy
This pilot study is will examine the pathways involved in allergic response, primarily in food allergy; specifically peanut allergy.
- Trial name
- NCT02194530
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Atopic Dermatitis
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine…
- Trial name
- BREEZE-AD4 (NCT03428100)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 103 sites in Austria, Belgium and 12 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Infant, Newborn
Moisturizer Mediated Prevention of Symptoms of Atopic Dermatitis in Early Childhood
In this study, it will be investigated if symptoms of atopic dermatitis of children with high familial risk will be delayed beyond the 6th or even 12th month of life by applying the SanaCutan Basiscreme.
- Trial name
- MOPAD (NCT04398758)
- Testing
- SanaCutan Basiscreme
- Where
- 10 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Atopic Dermatitis
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Clinical data suggest that treatment with OM-85, by inducing an early contact with bacterial extracts, could modulate the immunity of children with Atopic Dermatitis, and thus play an active role in the treatment of Atopic…
- Trial name
- NCT05222516
- Testing
- Broncho-Vaxom
- Where
- 28 sites in France, Germany and 2 more
- Volunteers
- 63 people
- Sponsor
- OM Pharma SA
Dermatitis, Atopic
Skin Irritation Study of GSK2894512 Cream
GSK2894512 is a novel anti-inflammatory agent that is currently under development for the topical treatment of atopic dermatitis and chronic plaque psoriasis.
- Trial name
- NCT02637206
- Testing
- GSK2894512 Cream, Vehicle Cream, Empty Patch
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Therapist-guided vs Self-guided CBT for AD: Non-inferiority Trial
The study aims to test the hypothesized non-inferiority of a self-guided digital intervention compared to a therapist-guided variant for people with atopic dermatitis (AD).
- Trial name
- NCT05517850
- Testing
- Therapist-guided cognitive behavioral therapy administered online, Self-guided digital intervention based on cognitive behavioral therapy
- Where
- Sweden
- Volunteers
- 168 people
- Sponsor
- Karolinska Institutet
Atopic Dermatitis
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to…
- Trial name
- ADfind (NCT06906497)
- Testing
- lebrikizumab
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 48 people
- Sponsor
- Johann E Gudjonsson MD PhD